You are here

FDA approves another in a new class of cholesterol drugs

Amgen's Repatha joins Sanofi's Praluent; but potency of medications raises a key question

New York

THE US Food and Drug Administration (FDA) has approved the second drug in a novel class of powerful cholesterol-lowering medications.

The new drug, Repatha, made by Amgen, is intended for people with extremely high cholesterol levels and those with heart disease who cannot